Market Insights: China Non Invasive Prenatal Testing Market 2017

China Potential Non–Invasive Prenatal Testing (NIPT) market is likely to reach more than US$ 1.7 Billion by 2024. Long–term Growth Projection and Development: • It is predicted that China Actual NIPT test volume will increase to 1.6 Million by 2024 • More than 3,00,000 NIFTY tests done in 2016 • Berry Genomics completes US$ 648 Million reverse merger in Shenzhen • Two–Child policy is likely to boost China NIPT market Growth in China NIPT market can be attributed to factors such as high incidence rate of babies born with Down syndrome, no risk of miscarriage with NIPT and shifting trend towards child bearing at advanced maternal age (35 years or older). High test cost, strict regulatory requirements and ethical hurdles is restraining the growth of China NIPT market. Due to expanding patient access to NIPT test, the China NIPT test market is poised to have a positive outlook in the year ahead. The research report titled “Non–Invasive Prenatal Testing(NIPT) Market Outlook 2024: China Opportunity and Demand Analysis, Market Forecast 2017–2024” examines the market dynamics, competitive landscape and discusses major trends. The study describes an in–depth analysis of the China actual and potential NIPT market.